Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from GlobalNewsWire (2014)

15:33 EST 14th November 2018 | BioPortfolio

Here are the most relevant search results for "GlobalNewsWire (2014)" found in our extensive news archives from over 250 global news sources.

More Information about GlobalNewsWire (2014) on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about GlobalNewsWire (2014) for you to read. Along with our medical data and news we also list GlobalNewsWire (2014) Clinical Trials, which are updated daily. BioPortfolio also has a large database of GlobalNewsWire (2014) Companies for you to search.

Showing News Articles 1–25 of 4,700+ from GlobalNewsWire (2014)

Wednesday 14th November 2018

Virbac: Availability of the quarterly financial information as of September 30, 2018

Virbac: Availability of the quarterly financial information as of September 30, 2018 Public release - November 14, 2018 The quarterly financial information as of September 30, 2018 is available: ·           on our website: corporate.virbac.com under the section Investors - Financial reports - 2018;·           or on request, under legal and regulatory conditions. ...

Terveystalo Plc: Financial calendar and AGM in 2019

Terveystalo Plc Stock Exchange Release 14 November 2018 at 09:05 a.m. EET In 2019, Terveystalo Plc will publish financial reports as follows: Financial Statements Bulletin 2018 on Thursday, February 14, 2019 Annual Report 2018 on week 9, 2019 Interim report for January-March 2019 on Thursday, May 9, 2019 Half-Year Report for January-June 2019 on Thursday, August 8, 20...

Terveystalo Group Interim Report 1 January - 30 September 2018

Terveystalo Plc. Interim report 14 November 2018 at 9:00 a.m. EET Strong earnings trend continued July-September 2018 in brief Revenue increased by 3.2 percent year-on-year to EUR 160.3 million (155.4)  Adjusted* EBITDA increased by 15.2 percent year-on-year to EUR 20.1 million (17.5)  EBITDA more than tripled year-on-year to EUR 27.6 million (7.6)  Adjusted* earni...

Customer evaluation of CADScor®System compares favorably against existing methods

Interim Report, January - September 2018 Malmö, November 14, 2018 Customer evaluation of CADScor®System compares favorably against existing methods "During the quarter we proudly reported that Kristianstad Central Hospital in Sweden evaluated the CADScor®System with a positive outcome. Due to the good result the hospitals clinical management team has now included the CADScor®Sy...

Tuesday 13th November 2018

Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London

Novartis International AG / Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Basel, November 13, 2018 - Novartis today announced that Alcon has filed an initial Form 20-F registratio...

Merger between Eckert & Ziegler BEBIG SA (BEBIG) and Eckert & Ziegler Strahlen - und Medizintechnik AG (EZAG) - Announcement of the filing of the Joint Terms of Merger

Press release  REGULATED INFORMATION Merger between Eckert & Ziegler BEBIG SA (BEBIG) and Eckert & Ziegler Strahlen - und Medizintechnik AG (EZAG) - Announcement of the filing of the common draft terms of the cross-border merger (Joint Terms of Merger) and availability of the merger documentation. Seneffe, Belgium, November 13, 2018. BEBIG announced the filing on 8 November...

Acarix (FN STO: ACARIX) today announced that the board of directors has appointed Per Persson to Chief Executive Officer

Press release Malmö, November 13, 2018 Acarix (FN STO: ACARIX) today announced that the board of directors has appointed Per Persson to Chief Executive Officer. Per Persson comes directly from the role as Chief Commercial Officer of Acarix. Christian Lindholm, who has served as interim CEO since February 2018, resumes his role as Chief Financial Officer. The changes are effective immediat...

Bavarian Nordic - Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program

COPENHAGEN, Denmark, November 13, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces that the share buy-back program, which was announced and initiated on November 9, 2018, has now been terminated, as the intended number of shares under the program has been repurchased. The program was executed in accordance with the provisions of Regulation (EU) No. 596/2014 of the Europea...

Inventiva: 2018 third quarter financial update

                                                Inventiva: 2018 third quarter financial update[1] Cash and cash equivalents[1]  at €68.1 million as of September 30, 2018  Revenues[1] for the first nine months of 2018 in line with projections at €2.3 million Daix (France), November 13, 2018 - Inventiva S.A. ("Invent...

Medtronic Receives CE Mark Approval for the Valiant Navion(TM) Thoracic Stent Graft System

Lower-Profile Thoracic Endovascular Aortic Repair (TEVAR) Device Broadens Treatable Patient Population with Thoracic Aortic Disease DUBLIN - November 13, 2018 - Medtronic plc (NYSE:MDT) today announced it has received CE Mark approval for the Valiant Navion(TM) thoracic stent graft system for the minimally invasive repair of all lesions of the descending thoracic aorta, including...

LIDDS receives approval from MPA to start Phase I study NZ-DTX-001

The Swedish Medical Product Agency has approved a first-in-human study, NZ-DTX-001, in which solid tumors will be treated with NanoZolid combined with docetaxel. This is LIDDS' second clinical project and will initially include patients at Karolinska University Hospital in Sweden. The Phase I study will assess the safety and tolerability of intratumoral treatment of patients with advan...

Ambu A/S: Annual Report 2017/18 (Earnings release)

Ambu ends the year with 15% organic growth and an EBIT margin of 21.6%. Following a 2.5 percentage point EBIT margin increase, Ambu is on track to realising the targets of its 2020 strategy. "We have now come to the end of the first year of our three-year strategy period, and we have created solid growth in our business. Our key figures and ratios are sa...

FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer

F. Hoffmann-La Roche Ltd / FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Triple-negative breast cancer is an aggressive disea...

Kiadis Pharma to present at upcoming investor conferences in November 2018

    Kiadis Pharma to present at upcoming investor conferences in November 2018 Amsterdam, The Netherlands, November 13, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that it is scheduled to present at the following investor conferences in Novembe...

Monday 12th November 2018

ERYTECH Reports Third Quarter 2018 Financial Results and Provides Business Update

Conference call and webcast scheduled for Tuesday, November 13 at 14:30 CET/8:30 am EST  Phase 3 trial for eryaspase in second line pancreatic cancer enrolling patients Phase 2 trial in triple-negative breast cancer to enroll patients by year end Cash position of €146.9 million ($170 million) as of September 30, 2018 LYON, France and CAMBRIDGE, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) --...

Enzymatica AB: Prospectus for Enzymatica's rights issue with preferential rights for existing shareholders published

Press release November 12, 2018 NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEELAND OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES BESIDES THOSE REQUIRED BY SWEDISH LAW. Pros...

Zealand Pharma to attend Jefferies and Bryan, Garnier & Co Healthcare Conferences

Press release - No. 23 / 2018 Zealand Pharma to attend Jefferies and Bryan, Garnier & Co Healthcare Conferences Copenhagen, November 12, 2018 - Britt Meelby Jensen, President and Chief Executive Officer of Zealand Pharma, will attend the Jefferies Healthcare Conference held November 14-15, 2018 in London, and the Bryan, Garnier & Co Annual Healthcare Conference held No...

Innate Pharma presented translational data from the Phase II of monalizumab and cetuximab at SITC

SITC 2018: FURTHER ANALYSES OF THE PHASE II STUDY OF THE COMBINATION OF MONALIZUMAB AND CETUXIMAB IN HEAD AND NECK PATIENTS SHOW ENCOURAGING SURVIVAL DATA IN BOTH SUBGROUPS OF IO-NAÏVE AND IO-PRETREATED SCCHN PATIENTS These data support the advancement of the clinical program, starting with the enrollment of an additional cohort of patients who received both prior platinum-bas...

Sunday 11th November 2018

New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients

Novartis International AG / New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enala...

Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause

ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL New analyses show reduction in non-fatal cardiovascular events is associated with a subsequent reduction in non-cardiovascu...

Friday 9th November 2018

Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2019

DUBLIN - November 9, 2018 - Medtronic plc (NYSE:MDT) announced today that it will report financial results for the second quarter of fiscal year 2019 on Tuesday, November 20, 2018. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for t...

Bavarian Nordic Announces Interim Results for the First Nine Months of 2018

COPENHAGEN, Denmark, November 9, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results in line with guidance for the first nine months of 2018 and business progress for the third quarter of 2018. Highlights A Biologics License Application for MVA-BN® smallpox vaccine (formerly IMVAMUNE®) was submitted to the U.S. Food and Drug Admini...

DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting

Montrouge, France, November 9, 2018 DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting Three abstracts on Viaskin Peanut accepted for oral presentation DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage

ESPERITE (ESP) expects publication of Annual Report 2017 before 17 November 2018

Amsterdam, The Netherlands - 09 November 2018 Esperite announces that the preparation of its Annual Report 2017 is nearly finalized and expects the publication of its Annual Report 2017 before 17 November 2018. About ESPERITEESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.To learn m...

Thursday 8th November 2018

EssilorLuxottica: Conditions for obtaining or consulting the documents prepared for the Ordinary and Extraordinary General Meeting of November 29, 2018

Conditions for obtaining or consulting the documents prepared for the Ordinary and Extraordinary General Meeting of November 29, 2018 PDF version of the news release Charenton-le-Pont, France (November 8, 2018 - 6:00 pm) - Shareholders are advised that an Ordinary and Extraordinary General Meeting will be held on Thursday, November 29, 2018 at 10:30 a.m. CET at the Espace G...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks